Overview
Intraocular medulloepithelioma, also known as diktyoma, is a rare embryonal neoplasm arising from the nonpigmented ciliary epithelium of the eye. This tumor originates from the medullary epithelium, which is the primitive neuroepithelial tissue that normally gives rise to structures of the eye during embryonic development. It is the most common tumor of the ciliary body in children and is typically diagnosed in early childhood, usually before the age of 10 years. Intraocular medulloepithelioma can be classified as benign (nonteratoid or teratoid) or malignant (nonteratoid or teratoid). Teratoid variants contain heteroplastic elements such as cartilage, brain tissue, or skeletal muscle. Key clinical features include a visible mass in the ciliary body region, decreased vision, leukocoria (white pupillary reflex), pain, glaucoma, lens subluxation or cataract, and neovascularization of the iris. The tumor may also present with a characteristic cyst or multiple cysts within the anterior segment of the eye. In some cases, the tumor can be associated with persistent hyperplastic primary vitreous or other developmental ocular anomalies. Rarely, intraocular medulloepithelioma has been reported in association with pleuropulmonary blastoma familial tumor and dysplasia syndrome linked to DICER1 mutations. Treatment depends on the size and extent of the tumor. Small, localized tumors may be managed with local resection (iridocyclectomy or partial lamellar sclerouvectomy), plaque brachytherapy, or cryotherapy. However, enucleation (surgical removal of the eye) remains the most common treatment, particularly for larger tumors or those with secondary complications such as glaucoma or extensive intraocular involvement. Malignant variants carry a risk of local invasion and, rarely, distant metastasis. Early diagnosis and treatment are critical to preserving vision when possible and preventing extraocular spread. Prognosis is generally favorable when the tumor is confined to the eye, but outcomes worsen significantly with extraocular extension.
Also known as:
Sporadic
Usually appears on its own, not inherited from a parent
Childhood
Begins in childhood, roughly ages 1 to 12
Treatments
No FDA-approved treatments are currently listed for Intraocular medulloepithelioma.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Intraocular medulloepithelioma at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Intraocular medulloepithelioma.
Community
No community posts yet. Be the first to share your experience with Intraocular medulloepithelioma.
Start the conversation →Latest news about Intraocular medulloepithelioma
No recent news articles for Intraocular medulloepithelioma.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Intraocular medulloepithelioma
What is Intraocular medulloepithelioma?
Intraocular medulloepithelioma, also known as diktyoma, is a rare embryonal neoplasm arising from the nonpigmented ciliary epithelium of the eye. This tumor originates from the medullary epithelium, which is the primitive neuroepithelial tissue that normally gives rise to structures of the eye during embryonic development. It is the most common tumor of the ciliary body in children and is typically diagnosed in early childhood, usually before the age of 10 years. Intraocular medulloepithelioma can be classified as benign (nonteratoid or teratoid) or malignant (nonteratoid or teratoid). Terato
How is Intraocular medulloepithelioma inherited?
Intraocular medulloepithelioma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Intraocular medulloepithelioma typically begin?
Typical onset of Intraocular medulloepithelioma is childhood. Age of onset can vary across affected individuals.
Which specialists treat Intraocular medulloepithelioma?
16 specialists and care centers treating Intraocular medulloepithelioma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.